Tamoxifen enhances the cytotoxic effects of the nitrosourea fotemustine. Results on human melanoma cell lines

Fischel, Jean‐Louis; Barbé, V.; Berlion, Maryse; Formento, Patricia; Berrile, J.; Bizzari, Jean-Pierre; Milano, Gérard

doi:10.1016/0959-8049(93)90220-a

Cited by 12 publications

(9 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results obtained confirm those of other studies in regard to the greater toxicity of melphalan compared with that of nitrosoureas such as CCNU (Garcia Reverte et al, 1995;Wang et al, 1989). Fotemustine showed similar or less toxicity in various melanoma lines 4,7,23,32,41,48) than did BCNU and CCNU (Fischel et al, 1990(Fischel et al, , 1993; appeared to induce fewer, although more rapidly repaired, DNA cross-linkings than other nitrosoureas (Tapiero, 19931, which would explain why it always showed less toxicity than melphalan and CCNU in our study. In regard to 4-HA, which, except when used with B16F10, was the least active antineoplastic agent, other studies have shown its response to vary considerably depending on the line used.…”

Section: Discussionsupporting

confidence: 50%

Azelaic Acid Has Sensitizing Effect in the Chemotherapeutic Treatment of Several Melanoma Cell Lines

Rodriguez-Vicente

Vicente-Ortega

Canteras-Jordana

1996

Pigment Cell Research

View full text Add to dashboard Cite

Chemotherapy for melanoma results in low response and must be reinforced with sensitizer compounds. We believed that azelaic acid (AZA) could modulate melanomas' resistance to antineoplastics. Therefore we tried to compare in vitro treatment with antineoplastics alone versus AZA treatment followed by antineoplastics. We carried out MTT assays to evaluate the cytotoxicity of melphalan, lomustine (CCNU), fotemustine, and 4-Hydroxyanisole (4-HA) on three melanoma lines (B16F10, SK-MEL-28, and SK-MEL-1), and the modulating effect of pretreatment with AZA (1 mM). AZA showed a dose-dependent antineoplastic activity on the three lines. Melphalan was the most active drug followed by CCNU, fotemustine, and 4-HA. The most sensitive line was B16F10 and the least sensitive was SK-meL-1. Previous treatment with AZA of B16F10 reinforced the effect of melphalan (2.5 times), CCNU (10 times), and fotemustine (14 times); whereas for SK-MEL-28 and SK-MEL-1, only the cytotoxicity of CCNU and fotemustine increased. An antagonist effect was produced by 4-HA on all three lines. We concluded that AZA enhances in vitro cytotoxicity of CCNU and fotemustine.

show abstract

Section: Discussionsupporting

confidence: 50%

Azelaic Acid Has Sensitizing Effect in the Chemotherapeutic Treatment of Several Melanoma Cell Lines

Rodriguez-Vicente

Vicente-Ortega

Canteras-Jordana

1996

Pigment Cell Research

View full text Add to dashboard Cite

show abstract

“…29, 30 Fischel et al 31 also showed that fotemustine toxicity in several melanoma lines were by the direct activation of the enzyme or due to the / 7b9f$$1039 01-12-98 10:42:45 cana W: Cancer elimination of endogenous inhibitors. 40 AZA has been radicals of the type produced by 4-HA and related drugs.…”

Section: Discussionmentioning

confidence: 99%

The effects of different antineoplastic agents and of pretreatment by modulators on three melanoma lines

Rodriguez-Vicente

Vicente-Ortega

Canteras-Jordana

1998

Cancer

View full text Add to dashboard Cite

show abstract

“…There are numerous reports of TAM enhancing the effectiveness of chemotherapeutic agents, ionizing radiation, and immune system-modulating agents in vitro. 9,[22][23][24][25][26][27] Using the human melanoma cell line T-289, McClay et al were the first to demonstrate a synergistic cytotoxic interaction between TAM and DDP. 5 Subsequently, others demonstrated a similar TAM/DDP effect in various malignant cell lines.…”

Section: Discussionmentioning

confidence: 99%

“…The median OS for patients treated without tamoxifen is 20.6 months (95% CI, 17.0 -24.7) and for patients treated with tamoxifen it is 18.4 months (95% CI, 16.4 -22.0). At 3 years, the FFS for patients without tamoxifen is 23% (95% CI, [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31], and for patients treated with tamoxifen it is approximately 22% (95% CI, 16 -29). The OS for patients without tamoxifen at 3 years is 30% (95% CI, [23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38], and for patients treated with tamoxifen it is 25% (95% CI, 19 -33).…”

Section: Survivalmentioning

confidence: 99%

A Phase III Trial Evaluating the Combination of Cisplatin, Etoposide, and Radiation Therapy With or Without Tamoxifen in Patients With Limited-Stage Small Cell Lung Cancer

McClay

Bogart²,

Herndon³

et al. 2005

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Based on both clinical and laboratory data that suggested that tamoxifen (TAM) enhanced the effectiveness of cisplatin (DDP)-based chemotherapy regimens, the Cancer and Leukemia Group B (CALGB) designed and initiated a prospective, randomized phase III trial to test the efficacy of the addition of high-dose TAM to a standard chemoradiation regimen of DDP and etoposide (VP-16) in patients with limited-stage small cell lung cancer (LS-SCLC). Between August 6, 1993, and January 15, 1999, 319 patients with LSSCLC were accrued to CALGB 9235. Patients were randomized to receive chemotherapy with or without high-dose TAM. Treatment on the non-TAM containing arm (arm 1) included DDP (80 mg/m2 intravenously day 1 only) and VP-16 (80 mg/m2 intravenously days 1-3) given every 3 weeks for a total of 5 cycles. Patients treated on arm 2 received the identical chemotherapy regimen as described here with the addition of high-dose TAM (80 mg orally twice per day), which was given for 5 days each cycle starting 1 day before the DDP. Thoracic radiation (XRT) given at 200 cGy 5 days per week to a total dose of 50 Gy began on day 1 of cycle 4 of chemotherapy and overlapped with cycle 5. Prophylactic cranial irradiation was offered to all patients who achieved a complete response or near-complete response. A total of 307 patients are evaluable for response. After the completion of the chemoradiation portion of the treatment, the overall response rate (ORR) was 88% for 154 patients treated without tamoxifen and 84% for 153 patients treated with tamoxifen with complete response (CR) rates of 49% and 50%, respectively. The median failure-free survivals of 12.3 months and 10.5 months and the overall survivals of 20.6 months and 18.4 months, respectively, were not statistically significant between the 2 arms. Toxicity was similar with and without tamoxifen. This phase III trial failed to demonstrate a positive effect on either the response or survival for the addition of TAM to standard etoposide-cisplatin-radiation management for patients with LS-SCLC. However, these data continue to support a positive effect of chemoradiation in the treatment of patients with LS-SCLC.

show abstract

Tamoxifen enhances the cytotoxic effects of the nitrosourea fotemustine. Results on human melanoma cell lines

Cited by 12 publications

References 17 publications

Azelaic Acid Has Sensitizing Effect in the Chemotherapeutic Treatment of Several Melanoma Cell Lines

Azelaic Acid Has Sensitizing Effect in the Chemotherapeutic Treatment of Several Melanoma Cell Lines

The effects of different antineoplastic agents and of pretreatment by modulators on three melanoma lines

A Phase III Trial Evaluating the Combination of Cisplatin, Etoposide, and Radiation Therapy With or Without Tamoxifen in Patients With Limited-Stage Small Cell Lung Cancer

Contact Info

Product

Resources

About